Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

@article{Dillman1996ImprovedSI,
  title={Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.},
  author={Robert Owen Dillman and James E. Herndon and Steven L. Seagren and William R. Eaton and Mark L. Green},
  journal={Journal of the National Cancer Institute},
  year={1996},
  volume={88 17},
  pages={
          1210-5
        }
}
BACKGROUND For many years, high dose radiation therapy was the standard treatment for patients with locally or regionally advanced non-small-cell lung cancer (NSCLC), despite a 5-year survival rate of only 3%-10% following such therapy. From May 1984 through May 1987, the Cancer and Leukemia Group B (CALGB) conducted a randomized trial that showed that induction chemotherapy before radiation therapy improved survival during the first 3 years of follow-up. PURPOSE This report provides data for… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 238 CITATIONS

FILTER CITATIONS BY YEAR

1958
2018

CITATION STATISTICS

  • 10 Highly Influenced Citations

  • Averaged 11 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Concurrent cisplatin / etoposide ( PE ) + chest radiation ( CRT ) followed by surgery for stages 3 A ( N 2 ) and 3 B non - small cell lung cancer : completed analysis of SWOG - 8805

  • K Albain, V Rusch, J Crowley, A Turrisi, T Rice, R Livingston
  • Proc ASCO
  • 1994

PE) + chest radiation (CRT) followed by surgery for stages 3A(N2) and 3B non-small cell lung cancer: completed analysis of SWOG-8805

  • C Blanke, R Ansari, R Mantravadi, R Gonin
  • Proc ASCO
  • 1994

Similar Papers

Loading similar papers…